VBI-S

Phase 3Small molecule

VVivacelle Bio

VBI-S is one of 27 small molecule programs targeting Septic Shock. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Septic ShockActive, not recruiting

Septic ShockPhase 3

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Septic Shock

#DrugCompanyPhaseTrials

VBI-S

VVivacelle Bio

Phase 3

2 2

Primaxin

Pfizer

Preclinical

2 3

Intropin

Pfizer

Preclinical

2 4

Zyvox

Pfizer

Preclinical

1 5

Doribax

Spravato

2 7

Cubicin

BBaxter Healthcare Corporation

Preclinical

1 8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Coly-Mycin M

PParkedale

Preclinical

1 10

Tygacil

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Septic Shock2 trials

VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

Unknown status·VVivacelle Bio·Phase 2·NCT04257136·20 enrolled

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

Recruiting·VVivacelle Bio·Phase 3·NCT06072430·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for VBI-S. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VBI-S compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VBI-S. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vivacelle Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVivacelle Bio

VBI-S

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Septic Shock2 trials

References

Drug Info

Quick Facts

Related News